See more : Chinlink International Holdings Limited (0997.HK) Income Statement Analysis – Financial Results
Complete financial analysis of SCYNEXIS, Inc. (SCYX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SCYNEXIS, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Zhejiang Giuseppe Garment Co., Ltd (002687.SZ) Income Statement Analysis – Financial Results
- Command Polymers Limited (COMMAND.BO) Income Statement Analysis – Financial Results
- QMC Quantum Minerals Corp (QMCQF) Income Statement Analysis – Financial Results
- Black Canyon Limited (BCA.AX) Income Statement Analysis – Financial Results
- ESS Tech, Inc. (GWH) Income Statement Analysis – Financial Results
SCYNEXIS, Inc. (SCYX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.scynexis.com
About SCYNEXIS, Inc.
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 140.14M | 5.09M | 13.16M | 0.00 | 121.00K | 257.00K | 257.00K | 257.00K | 257.00K | 1.26M | 16.86M | 16.84M |
| Cost of Revenue | 15.62M | 628.00K | 312.00K | 303.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.45M | 16.31M | 14.36M |
| Gross Profit | 124.52M | 4.46M | 12.85M | -303.00K | 121.00K | 257.00K | 257.00K | 257.00K | 257.00K | -14.19M | 552.00K | 2.47M |
| Gross Profit Ratio | 88.85% | 87.66% | 97.63% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | -1,129.78% | 3.27% | 14.69% |
| Research & Development | 30.93M | 27.26M | 23.77M | 36.52M | 38.39M | 21.56M | 18.33M | 20.08M | 16.44M | 8.29M | 4.36M | 8.93M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.68M | 8.25M | 8.00M | 12.17M | 7.57M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 48.00K | 0.00 | 0.00 |
| SG&A | 20.92M | 62.96M | 49.92M | 14.63M | 10.65M | 8.68M | 8.25M | 8.00M | 12.17M | 7.62M | 4.38M | 4.74M |
| Other Expenses | 0.00 | 3.00K | -13.00K | -334.00K | 538.00K | 0.00 | 0.00 | 0.00 | 0.00 | -10.00K | 4.38M | 12.00K |
| Operating Expenses | 51.85M | 90.22M | 73.68M | 50.82M | 49.04M | 30.24M | 26.58M | 28.07M | 28.61M | 15.90M | 8.74M | 13.67M |
| Cost & Expenses | 67.47M | 90.85M | 73.99M | 50.82M | 49.04M | 30.24M | 26.58M | 28.07M | 28.61M | 15.90M | 25.05M | 28.03M |
| Interest Income | 3.95M | 1.42M | 24.00K | 189.00K | 805.00K | 967.00K | 386.00K | 185.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.13M | 5.20M | 2.66M | 1.18M | 986.00K | 2.05M | 1.86M | 351.00K | 11.00K | 803.00K | 11.89M | 972.00K |
| Depreciation & Amortization | 810.00K | 813.00K | 577.00K | 303.00K | 285.00K | 53.00K | 41.00K | 26.00K | 447.00K | 1.24M | 1.33M | 1.49M |
| EBITDA | 73.48M | -59.91M | -31.41M | -51.15M | -51.27M | -17.10M | -23.16M | -29.51M | -27.90M | -2.19M | -13.76M | -9.71M |
| EBITDA Ratio | 52.43% | -1,675.94% | -468.93% | 0.00% | -40,196.69% | -11,269.65% | -10,075.10% | -10,780.54% | -10,856.81% | -1,128.50% | -61.39% | -74.91% |
| Operating Income | 72.67M | -85.76M | -60.83M | -51.15M | -48.92M | -29.98M | -26.32M | -27.82M | -28.35M | -14.65M | -7.20M | -7.78M |
| Operating Income Ratio | 51.85% | -1,684.48% | -462.09% | 0.00% | -40,430.58% | -11,666.54% | -10,241.25% | -10,823.74% | -11,030.74% | -1,166.16% | -42.74% | -46.23% |
| Total Other Income/Expenses | -5.49M | 18.25M | 24.88M | -7.18M | -4.79M | 10.78M | 1.26M | -2.17M | 11.00K | 7.88M | -23.26M | -281.00K |
| Income Before Tax | 67.18M | -67.51M | -35.95M | -58.33M | -53.71M | -19.20M | -25.06M | -29.99M | -28.34M | -6.77M | -30.46M | -11.48M |
| Income Before Tax Ratio | 47.94% | -1,326.05% | -273.14% | 0.00% | -44,388.43% | -7,472.37% | -9,750.97% | -11,668.87% | -11,026.46% | -538.93% | -180.70% | -68.17% |
| Income Tax Expense | 138.00K | -4.70M | -3.09M | -3.15M | 1.52M | -6.74M | 1.86M | 351.00K | -4.29M | -1.17M | 11.89M | 984.00K |
| Net Income | 67.04M | -62.81M | -32.87M | -55.19M | -55.23M | -12.47M | -25.06M | -29.99M | -32.62M | -4.23M | -30.46M | -11.48M |
| Net Income Ratio | 47.84% | -1,233.73% | -249.68% | 0.00% | -45,647.93% | -4,851.36% | -9,750.97% | -11,668.87% | -12,693.77% | -337.10% | -180.70% | -68.17% |
| EPS | 1.40 | -1.47 | -1.25 | -5.15 | -9.85 | -2.84 | -9.37 | -15.75 | -26.82 | -7.48 | -192.64 | -72.58 |
| EPS Diluted | 1.39 | -1.47 | -1.25 | -5.15 | -9.85 | -2.84 | -9.37 | -15.75 | -26.82 | -7.13 | -192.64 | -72.58 |
| Weighted Avg Shares Out | 47.85M | 42.61M | 26.38M | 10.72M | 5.61M | 4.39M | 2.67M | 1.90M | 1.22M | 566.33K | 158.13K | 158.13K |
| Weighted Avg Shares Out (Dil) | 48.39M | 42.61M | 26.38M | 10.72M | 5.61M | 4.39M | 2.67M | 1.90M | 1.22M | 593.71K | 158.13K | 158.13K |
SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update
JERSEY CITY, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the third quarter ended September 30, 2024.
SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit
JERSEY CITY, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will participate in...
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024
JERSEY CITY, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced upcoming presentations of preclinical efficacy and pharmacokinetic data on its second-generation...
SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference
JERSEY CITY, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will make a...
SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update
JERSEY CITY, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the second quarter ended June 30, 2024.
SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports
JERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $10 million development milestone payment under...
3 Stocks Under $10 With the Potential for Massive Gains
Investing in small-cap stocks can be a gateway to high returns, mainly when these companies exhibit strong growth fundamentals and strategic market positioning. Here, the focus is on three stocks to buy under $10.
3 Dirt-Cheap Drug Developers With Blockbuster Potential
One of the more exciting yet admittedly risky types of investing is buying into cheap drug developer stocks early in their company life cycle. That's because the world of drug development and biotech research tends to rely on big market-moving...
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
Every investment category must answer the big question, why? For undervalued biotech stocks, it comes down to advantaging a supremely relevant sector without paying full price.
Hidden Gems: 3 Under-$10 Stocks Poised for 500% Growth by 2025
The ability to recognize possibilities while investing can frequently be the difference between stagnation and growth in an unstable and changing economic environment. Here are three exciting stocks in technology, insurance, and medicines.
Source: https://incomestatements.info
Category: Stock Reports